| Objective: To explore the relationship between the expression of DDX3 and uPAR in CRC and its hepatic metastasis foci and its clinical pathologic features(sex,age,tumor site,differentiation type,CEA volume,tumor size,invasion depth,TNM staging,lymph node metastasis,liver metastasis)though detecting the expression of DEAD-box polypeptide 3(DDX3)and urokinase-type plasminogen activator receptor(uPAR)in CRC and its hepatic metastasis foci.To further study the role of DDX3 and uPAR in the occurrence,development,distant metastasis,especially in liver metastasis of CRC and provided useful clues.Methods: Collecting the 60 postoperative specimens of CRC patients from January 2013 to June 2015 of the affiliated Hospital of Northern Sichuan Medical College,the liver metastases specimen were 14;The normal tissue specimens of CRC adjacent to 60 cases of CRC,the normal tissues adjacent to hepatic metastatic foci were 14.The expression of DDX3 and uPAR in specimens was examined by immunohistochemical method,and the correlation between DDX3 and uPAR expression in CRC and its hepatic metastasis foci and the clinical pathological features of CRC were analyzed.All data is analysed by IBM SPSS Statistics 21.0 software.Results: The positive expression rate of DDX3 in CRC specimens was 63.33%,the positive expression rate of the normal tissue specimens of CRC was 20.00%,the difference was statistically significant(X~2=21.429,P<0.05);The positive expression rate of 92.86% in CRC specimens of hepatic metastases was 14.29%,and the difference was statistically significant(X~2=14.359,P<0.05).The positive expression rate of uPAR in CRC specimens was 68.33%,the positive expression rate of the normal tissue specimens of CRC was 23.33%,the difference was statistically significant(X~2=22.691,P<0.05);The positive expression rate of 100.00% in CRC specimens of hepatic metastases was 7.14%,and the difference was statistically significant(X~2=20.677,P<0.05).The expression of DDX3 in the patients with CRC(X~2=0.027,P>0.05),age(X~2=0.000,P>0.05),tumor site(X~2=0.058,P>0.05)was not statistically significant,but in differentiation type(X~2=5.021,P<0.05),CEA(X~2=3.305,P<0.05),tumor size(X~2=3.326,P<0.05),infiltration depth(X~2=9.569,P<0.05),TNM Staging(X~2=14.712,P < 0.05),lymph node metastasis(X~2=10.811,P<0.05),liver metastasis(X~2=5.893,P<0.05)were statistically significant.The expression of uPAR in the patients with CRC(X~2=0.000,P>0.05),age(X~2=0.000,P>0.05),tumor site(X~2=0.094,P>0.05)was not statistically significant,but in differentiation type(X~2=3.371,P<0.05),CEA(X~2=6.133,P<0.05)tumor size(X~2=6.318,P<0.05),infiltration depth(X~2=9.569,P<0.05),TNM Staging(X~2=15.561,P<0.05),lymph node metastasis(X~2=8.594,P<0.05),liver metastasis(X~2=6.661,P<0.05)were statistically significant.Both DDX3 and uPAR were expressed in CRC specimens,they were co-expressed in 33 of 60 cases,positive total expression rate was 55.00%.Using Spearman correlation analysis both were negatively correlated(r=-0.523,-0.8<r?-0.5,P<0.05).Conclusion:(1)DDX3 was significant down-regulated in CRCs and metastatic liver focuses compared with adjacent normal tissues;uPAR was significant up-regulated in CRCs and metastatic liver focuses compared with adjacent normal tissues.(2)The expression levels of DDX3 and uPAR were obviously correlated with parts of CRC patients' clinicopathological features,this results suggested the expression levels of DDX3 and uPAR could become potential biomarkers for CRC diagnosis and prognostic evaluation and therapeutic target of CRC treatment.(3)The expression levels between DDX3 and uPAR present moderate negative correlation,It is suggested that the variation of expression level of DDX3 and uPAR may be reversed during the development of CRC,and the degree of this variation may be relevant. |
PDF Full Text Request